Kidney Health and the Hidden Lipid Risk
People who live with long‑term kidney problems face a higher chance of heart trouble than those without. This extra risk comes from the kidneys themselves and from changes in how fats move through the body, such as an imbalance in cholesterol levels.
Statins: A Partial Solution
Doctors usually give statin drugs to help control bad fats for those with mild or moderate kidney issues.
- Target: Low‑density lipoprotein (LDL) cholesterol
- Gap: Little effect on the particle called Lp(a)
Because of this gap, doctors must look beyond standard tests when deciding how dangerous a patient’s heart condition might be.
Dialysis Patients: A Tough Decision
In patients whose kidneys have failed completely and who are on dialysis, statins haven’t proven helpful if they had never had a heart attack or stroke before. This leaves clinicians unsure about the best way to tackle fat problems in these individuals.
The Lp(a) Connection
Recent studies show that when Lp(a) levels are high—over 105 nanomoles per liter—the risk for plaque build‑up and hardening of arteries rises sharply.
- Mechanism: Lp(a) carries cholesterol to the walls of blood vessels, encouraging inflammation and calcium deposits that can lead to blockages.
Unfortunately, there are no approved drugs that specifically lower Lp(a) yet.
- Some new medicines are being tested in large Phase III trials, but they are not yet part of everyday care.
Until these treatments become available, doctors focus on managing other risk factors like blood pressure and overall cholesterol, while monitoring Lp(a) as a warning sign.
A Call for Routine Screening
The growing evidence that high Lp(a) adds to heart risk in kidney patients urges a shift in how doctors assess danger. Routine screening for this particle could help identify people who need more aggressive prevention, even if their standard cholesterol numbers look okay.
Future research may bring targeted Lp(a) therapies that could change the outlook for those with kidney disease.
